

20 CRISPR patents granted to the Life Science business of Merck KGaA, Darmstadt, Germany

Leading the way in genome-editing technology

CRISPR Integration:

CRISPR/Cas9 System for Insertion in Eukaryotic Cells

Compositions and use of CRISPR/Cas9 to integrate a new sequence of DNA after cutting genomic DNA

Patents Received

● 2017 ○ 2018 ▲ 2019

● Patents Pending

proxy-CRISPR:

New genome-editing technique that makes CRISPR more efficient, flexible and specific

Opens up the genome for modification of DNA, providing more experimental options, faster results

Patents Received

▲ 2019

● Patents Pending

Paired Nickase:

Cleavage of Chromosomal Sequences using Dual Nickases

Compositions and use of two Cas9 nickases to cut genomic DNA, optionally followed by integration of new DNA sequence

Patents Received

○ 2018 ▲ 2019

● Patents Pending



EMD
SERONO

MILLIPORE
SIGMA

EMD
PERFORMANCE
MATERIALS

The businesses of Merck KGaA, Darmstadt, Germany operate as EMD Serono, MilliporeSigma and EMD Performance Materials in the U.S. and Canada

© 2019 Merck KGaA, Darmstadt, Germany and/or its affiliates. All Rights Reserved.
EMA Serono, MilliporeSigma, EMD Performance Materials and the vibrant M are trademarks of Merck KGaA, Darmstadt, Germany or its affiliates. All other trademarks are the property of their respective owners. Detailed information on trademarks is available via publicly accessible resources. 2019 - 22382

